admin

admin

TScan Reprioritizes Around In Vivo TCR-T

TScan is cutting approximately 75% of its workforce, eliminating internal manufacturing and pausing further Phase III ALLOHA-2 enrollment because it lacks sufficient capital to complete the study. Resources will shift to preclinical in-vivo-engineered TCR-T…

Medicus Licenses Pfizer’s CD228V ADC

Medicus Pharma licensed exclusive worldwide rights to Pfizer’s early clinical-stage CD228-targeted antibody-drug conjugate, CD228V/PF-08046031, for human disease. Medicus paid $12 million upfront, owes $15 million on the first anniversary, received $2 million in restricted…